A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to accelerate the development of better treatment regimens for tuberculosis.
Scientists from Weill Cornell Medicine and the Dana-Farber Cancer Institute have developed new AI tools tailored to digital pathology, a growing field that uses high-resolution digital images created from tissue samples to help diagnose disease.
Vaccinating mothers against RSV during late pregnancy to protect their newborns is not associated with an increased risk of preterm birth or other poor outcomes, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
One in five of the bacterial strains that cause typhoid fever have genetic variations in their external layer, called Vi capsule, that provide higher virulence, higher infectivity and high antibiotic resistance, Cornell researchers have discovered.
A multinational team led by Weill Cornell Medicine investigators developed a test for an HIV strain that disproportionately affects women and will benefit patients around the world.
Cornell researchers have developed a bioelectric device that can detect and classify new variants of coronavirus, and potentially other viruses, such as measles and influenza, to identify those that are most harmful.
ACT for Youth, which promotes adolescent health and well-being in New York state, has been awarded $5 million to help local health departments improve care for youth with special needs.
Cornell inventors are turning visionary ideas into tangible solutions to global challenges. Cornell’s Center for Technology Licensing celebrated their achievements at its inaugural Bearers of Innovation event.
